Scarica l'app Stockscreener
34.67
3.37%
-1.21
Dopo l'orario di chiusura:
34.68
0.010
+0.03%
Precedente Chiudi:
$35.88
Aprire:
$35.26
Volume 24 ore:
129.05K
Relative Volume:
0.42
Capitalizzazione di mercato:
$1.54B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-2.17%
1M Prestazione:
+0.32%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$34.22
$36.18
Intervallo di 1 settimana:
$34.22
$38.70
Portata 52W:
$24.15
$40.17
Avalyn Pharma Inc Stock (AVLN) Company Profile
Nome
Avalyn Pharma Inc
Settore
Industria
Telefono
(206) 707-0340
Indirizzo
105 W FIRST ST., BOSTON
Compare AVLN vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVLN
Avalyn Pharma Inc
|
34.67 | 1.59B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Avalyn Pharma Inc Borsa (AVLN) Ultime notizie
Bank of New York Mellon Corp Acquires New Shares in Avalyn Pharma Inc. $AVLN - marketbeat.com
Avalyn Pharma presents AP01 lung distribution modeling data By Investing.com - Investing.com Canada
Avalyn Pharma presents AP01 lung distribution modeling data - Investing.com
People with lung scarring are willing to travel for trials, Avalyn survey finds - Stock Titan
Avalyn Pharma Inc. (NASDAQ:AVLN) Given Average Rating of "Moderate Buy" by Brokerages - marketbeat.com
Avalyn Pharma Inc. Common Stock (NASDAQ: AVLN) Stock Price, News & Analysis - Kalkine
AVLN Options Overview History for Avalyn Pharma Stock - Barchart.com
Braidwell LP Invests $26.38 Million in Avalyn Pharma Inc. $AVLN - marketbeat.com
Montanova Capital LLC Takes Position in Avalyn Pharma Inc. $AVLN - marketbeat.com
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026 - Barchart.com
Avalyn will present a model of how an inhaled treatment may spread through the lungs - Stock Titan
AVLN Options Volatility — NASDAQ:AVLN - TradingView
AVLN Options Chain — NASDAQ:AVLN - TradingView
Avalyn Pharma (NASDAQ:AVLN) Sets New 1-Year HighHere's Why - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Avalyn Pharma (NASDAQ:AVLN) Cut to Sell at Wall Street Zen - marketbeat.com
Novo Holdings A/S (AVLN) discloses 8.8% beneficial stake in Avalyn Pharma - Stock Titan
Jefferies Maintains Avalyn Pharma(AVLN.US) With Buy Rating, Maintains Target Price $52 - Moomoo
Morgan Stanley Maintains Avalyn Pharma(AVLN.US) With Buy Rating, Raises Target Price to $57 - Moomoo
Avalyn Pharma (NASDAQ:AVLN) Hits New 52-Week High Following Better-Than-Expected Earnings - MarketBeat
AVLN SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Avalyn Pharma Q2 Results: EPS misses estimate by 22.64% - scanx.trade
Avalyn Pharma (NASDAQ:AVLN) Trading Up 8.2% Following Better-Than-Expected Earnings - MarketBeat
Form 8K Avalyn Pharma Inc. For: 12 August By Investing.com - Investing.com Nigeria
Avalyn Pharma Inc. Q2 2026: Net loss $(28.9M), EPS $(0.98) — 10-Q Summary - TradingView
Avalyn Pharma's Q2 Net Loss Widens - Yahoo Finance
Avalyn: Q2 Earnings Snapshot - AOL.com
AVLN: Completed Phase 2b trial enrollment and secured $413.5M cash runway into 2029 - TradingView
AVLN: Net loss widened on higher R&D spend; IPO proceeds extend cash runway into 2029 - TradingView
Avalyn Pharma reports Q2 2026 net loss $28.9M; cash $413.5M, runway into 2029 - TradingView
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights - marketscreener.com
Avalyn Pharma Inc. (NASDAQ:AVLN) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Avalyn Pharma (AVLN): Norwest Venture Partners discloses 5.1% ownership stake - Stock Titan
Biotech Stocks At 52-Week HighsHALO +20% On Q2 Results, FENC, AVLN, AMLX, CHE - RTTNews
Avalyn Pharma Inc.common stock (AVLN) Stock Price, News, Quote & History - FinancialContent
Avalyn Pharma (NASDAQ:AVLN) Reaches New 52-Week HighTime to Buy? - MarketBeat
Avalyn Pharma (AVLN) Institutional Ownership 2026 - MarketBeat
Avalyn Pharma CEO Baranowski: Inhaled Drugs Cut Lung Function Decline to 0.4%, Opening a $42 Billion Market Oral Therapies Can't Reach - finance.biggo.com
Howard Lazarus Net Worth (2026) - GuruFocus
Avalyn Pharma (NASDAQ:AVLN) Shares Gap DownTime to Sell? - MarketBeat
Avalyn Pharma Inc. Revenue Breakdown – NASDAQ:AVLN - TradingView
AVLN|Avalyn Pharma Ord Shs (Proposed)|Price:27.950|Chg%:-1.780 - TradingKey
Adam H. Golden Net Worth (2026) - GuruFocus
Enterprise value to revenue forward of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Price to sales forward of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Price to book forward of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Avalyn Pharma Inc (AVLN:UW): Stock Price, Quote and News - BNN Bloomberg
Avalyn Pharma Inc. (NASDAQ:AVLN) Receives Average Rating of "Buy" from Analysts - MarketBeat
Avalyn Pharma (NASDAQ:AVLN) Shares Up 5.3%Here's Why - MarketBeat
Melissa Rhodes Net Worth (2026) - GuruFocus
The Signal - Nasdaq
Avalyn Pharma Inc Azioni (AVLN) Dati Finanziari
Non sono disponibili dati finanziari per Avalyn Pharma Inc (AVLN). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):